Introduction {#s0005}
============

Urolithiasis affects ≈12% of the population globally [@b0005]. Ureteric stones represent ≈20% of urolithiasis cases, from which ≈70% are situated in the lower third of the ureter and termed 'distal ureteric stones' (DUS) [@b0010]. Over the last two decades, the management of ureteric stones had changed greatly, especially after the introduction of shockwave lithotripsy (SWL) and ureteroscopy, as minimally invasive treatments. However, these treatments are expensive and are not risk free. The overall complications after ureteroscopy have been estimated to be 10--20% in different studies, in which major complications, such as ureteric avulsions, perforations and strictures, occurred in 35% of cases [@b0015].

Recently, α-blockers used as medical expulsive therapy (MET) have replaced minimally invasive procedures as the first line of management for small ureteric stones [@b0020], [@b0025]. The clinical benefit of α-blockers for treating DUS had been shown in two meta-analysis with a high level of evidence, in which spontaneous stone passage in patients given α-blockers were 52% and 44% greater than those not given such medications [@b0030], [@b0035].

Both the AUA [@b0040] and the European Association of Urology (EAU) [@b0045] recommend α-blockers for the treatment of ureteric stones. Recently, the α~1A~-adrenoceptor subtype has been shown to play the major role in mediating phenylephrine-induced contraction of the human isolated ureter [@b0050]. In the human ureter, silodosin (a selective α~1~-adrenoceptor blocker) was found to be more effective than an α~1D~-adrenoceptor blocker in noradrenaline-induced contraction [@b0055]. However, published data are limited on the use of silodosin as MET for DUS; thus we conducted a prospective randomised study to compare the efficacy and safety of silodosin vs tamsulosin as MET for single, symptomatic, uncomplicated DUS in adults.

The objective of the present study was to compare the efficacy and safety of silodosin (8 mg) vs tamsulosin (0.4 mg) as a MET in the management of DUS in terms of stone clearance rate and stone expulsion time, and adverse effects.

Patients and methods {#s0010}
====================

This prospective randomised study was conducted between March 2014 and September 2014, the cohort comprised 115 adult patients (74 men and 41 women) who presented with a symptomatic, unilateral, single, uncomplicated DUS of ⩽10 mm.

Patients were randomised 1:1, with the first case selected using a sealed envelope method. The sample size was calculated using Epi Info 6 version 6.04d program software (WHO, Geneva, Switzerland) and the difference in stone expulsion time between the two groups was considered as clinical equivalence with a confidence of 95% and power of 80%. The exclusion criteria were: a single kidney, bilateral ureteric stones, renal impairment, UTI, high-grade hydronephrosis (Grades 3 and 4 according to Society of Fetal Ultrasound, SFU), and any history of previous endoscopic or surgical interventions.

All patients were diagnosed by plain abdominal radiograph of the kidneys, ureters and bladder (KUB), ultrasonography, and non-enhanced spiral CT (in some cases). Every patient provided informed written consent after receiving information about the nature of the study, time to study end, adverse effects, and the possibility of intervention if needed. The patients were randomly divided into two groups; Group A (58 patients) received a single dose of silodosin (8 mg) daily, and Group B (57 patients) received a single dose of tamsulosin (0.4 mg) daily. For ureteric colic, diclofenac sodium (50 mg tablet) was prescribed for analgesia. We used a visual analogue scale for pain assessments.

Follow-up was performed every week by asking the patient about stone passage, attacks of renal colic, analgesic requirements, time of stone passage, and symptoms related to side-effects of the drugs. Radiological assessment was done every 2 weeks with plain KUB and ultrasonography for radio-opaque stones, and non-contrast spiral CT for radiolucent stones at the end of the study. All patients were advised to increase water intake and to filter their urine to detect stone expulsion. The primary endpoint was the rate of stone clearance and the secondary endpoint was stone expulsion time. The patients were followed-up until stone passage was confirmed by plain KUB or non-contrast spiral CT or at the end of the study period (4 weeks) and surgical intervention.

Data were checked, entered and analysed using SPSS version 20. Data were presented as the mean (SD) for quantitative variables, and number and percentage for categorical variables; the chi-squared, Fisher's exact test or *t*-test were used when appropriate. The threshold level of significance was fixed at 5% for all the above mentioned tests. The results were considered:•Significant when the probability of error is \<5% (*P* \< 0.05).•Non-significant when the probability of error is \>5% (*P* \> 0.05).•Highly significant when the probability of error is \<0.1% (*P* \< 0.001).

Our study protocol was approved by the Hospital Research and Ethics Committee, and all patients provided an informed written consent for participation.

Results {#s0015}
=======

The patients' ages in both groups ranged between 21 and 55 years. Three patients in group A and one patient in group B withdrew before treatment because of either spontaneous stone passage (one patient) or voluntary withdrawal (three). Four patients (two in each group) discontinued the treatment in the first few days due to orthostatic hypotension and were excluded from the study. During follow-up, four patients were lost (one in group A and three in group B). Thus the total number of patients analysed was 52 in Group A and 51 in Group B ([Fig. 1](#f0005){ref-type="fig"}).

There were no significant differences among the two groups for patient's age, gender, stone laterality, and stone size ([Table 1](#t0005){ref-type="table"}).

The stone clearance rate was significantly different between the groups, at 83% (43/52 patients) in Group A vs 57% (29/51 patients) in Group B (*P* = 0.007). In Group A (silodosin), the stone expulsion time was also significantly shorter than in Group B (tamsulosin), at a mean (SD) of 13.3 (4.1) vs 16.7 (5.4) days, respectively (*P* \< 0.001; [Fig. 2](#f0010){ref-type="fig"}). Also, there were fewer ureteric colic episodes and less analgesic requirement in Group A ([Table 2](#t0010){ref-type="table"}).

Orthostatic hypotension was encountered in two patients (3.8%) in Group A, who discontinued treatment, and four patients (7.8%) in Group B, of which two patients discontinued treatment. Abnormal ejaculation was recorded in nine patients (17.3%) in Group A (silodosin) and in three patients (5.9%) in Group B (tamsulosin), which was statistically nonsignificant; however, no patient discontinued the study, as they were informed about this adverse effect and that it was a reversible condition.

Discussion {#s0020}
==========

Ureteroscopy and SWL remain the most effective treatments for DUS; however, they are expensive and not risk free. Spontaneous stone expulsion can occur in up to 50% of cases, nevertheless, many complications such as ureteric colic, UTI, and hydronephrosis, may occur. Recently, the use of various adjuvant medications as MET for DUS has helped to reduce pain, complications, and increase the rate of stone clearance [@b0060], [@b0065].

The α~1A~- and α~1D~-adrenoceptors are the most abundant subtypes in the distal ureter, stimulation of these α~1-~adrenoceptors leads to increases in both the frequency of ureteric peristalsis and the force of ureteric contractions. However, blockade of these receptors decreases basal ureteric tone, decreases peristaltic frequency and amplitude, leading to a decrease in intra-luminal pressure while the rate of urine transport increases, and thus increasing the chance of stone passage [@b0070].

Highly selective α~1A~-adrenoceptor blockers have been developed to minimise the cardiovascular adverse effects while maintaining their efficacy on the urinary tract [@b0075]. Tamsulosin is a selective α~1~-blocker with a 10-fold greater affinity for the α~1A-~ and α~1D-~adrenoceptor subtypes than for the α~1B~-adrenoceptor subtype, while the affinity of silodosin for the α~1A~-adrenoceptor subtype is ≈162- and 50-fold greater than its affinity for the α~1B~- and α~1D~-adrenoceptor subtypes respectively, which explain the weak cardiovascular adverse effects of silodosin [@b0075].

In patients presenting with DUS of ⩽10 mm without the use of MET, the reported spontaneous stone clearance rates are between 35.2% and 61%, with mean expulsion times ranging between 9.87 and 24.5 days [@b0080], [@b0085], [@b0090], [@b0095]. Several factors can affect spontaneous stone clearance of DUS including: stone size, site, number, and also the presence or absence of ureteric smooth muscle spasm and/or submucosal oedema. Coll et al. [@b0100], found a direct relationship between stone size and spontaneous clearance.

In our present study, the stone clearance rate was significantly higher in the silodosin group compared with the tamsulosin group, at 83% and 57%, respectively (*P* = 0.007). Our results are in agreement with those of Gupta et al. [@b0105], who reported stone clearance rates of 82% and 58% for their silodosin and tamsulosin groups, respectively; and also in agreement with those of Kumar et al. [@b0110], who reported stone clearance rates of 83.3% and 64.4% for their silodosin and tamsulosin groups, respectively. However, Imperatore et al. [@b0115] reported a nonsignificant difference of stone clearance rates between silodosin (88%) and tamsulosin (84%). While Sur et al. [@b0120] reported a stone clearance rate of 52% with silodosin treatment of all ureteric stones (upper, middle and lower), which may reduce the overall efficacy as α-receptors are more abundant in the distal ureter.

The mean (SD) stone expulsion time was significantly shorter in the silodosin group vs the tamsulosin group, at 13.3 (4.1) vs 16.7 (5.2) days, respectively (*P* \< 0.001). These results are also in agreement with those of Gupta et al. [@b0105], who also reported significantly shorter mean (SD) stone expulsion times in the silodosin vs the tamsulosin group, at 12.5 (3.5) vs 19.5 (7.5) days, respectively; and also in agreement with Kumar et al. [@b0110] who reported mean (SD) stone expulsion times of 16.5 (4.6) days in the tamsulosin group and 14.8 (3.3) days in the silodosin group. However, Imperatore et al. [@b0115] reported a shorter mean stone expulsion time for both silodosin and tamsulosin of 6.7 and 6.5 days, respectively.

For safety issues and adverse effects, both drugs are safe and well tolerated, and the most frequently encountered side-effect in the present study was retrograde ejaculation, which was reported in nine (17.3%) and three patients (5.9%) in the silodosin and tamsulosin groups, respectively, which was not statistically significantly different (*P* = 0.135). However, no patient discontinued the treatment because of retrograde ejaculation and the condition was reversible, resolving within a few days of cessation of treatment. However, Imperatore et al. [@b0115] reported that retrograde ejaculation was significantly different between silodosin (2%) and tamsulosin (8%). In the present study, six patients had orthostatic hypotension, two in the silodosin group (3.8%) and four in the tamsulosin group (7.8%), which was not statistically significantly different. These results are in agreement with those of Kumar et al. [@b0110], who reported orthostatic hypotension in 3.3% and 6.6% in the silodosin and tamsulosin groups, respectively; and also in agreement with Imperatore et al. [@b0115] who reported a nonsignificant difference in orthostatic hypotension of 2% and 6% in the silodosin and tamsulosin groups, respectively. However, only four patients in our present study discontinued treatment (two in each group) and were excluded from the study, while two patients in the tamsulosin group with orthostatic hypotension completed the treatment course.

The results from the present study show a low mean (SD) number of pain episodes in both groups of 1.3 (0.4) and 1.4 (0.3) in the silodosin and tamsulosin groups, respectively, which was not statistically significantly different (*P* = 0.15). These results were in agreement with Kumar et al. [@b0110], who reported a mean (SD) number of pain episodes of 0.8 (0.9) and 1.70 (1.2) in the silodosin and tamsulosin groups, respectively; and also in agreement with Imperatore et al. [@b0115] who reported a nonsignificant difference between the silodosin and tamsulosin groups of 1.6 (0--4) and 1.7 (0--4), respectively. The pain relieving effects of the α-blockers may be explained by the blocking of C-fibres responsible for mediating pain [@b0125].

In conclusion, silodosin is more effective than tamsulosin in the management of DUS for the stone clearance rate and stone expulsion time; however, a multicentre study on a larger scale is needed to confirm its efficacy and safety.
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###### 

The patients' demographic and stone data.

  Variable                      Group A (silodosin 8 mg)   Group B (tamsulosin 0.4 mg)   *P*
  ----------------------------- -------------------------- ----------------------------- --------------------------------------
  Mean (SD; range) age, years   33.6 (9.9; 21--53)         35.5 (11.3; 24--55)           0.3[⁎](#tblfn1){ref-type="table-fn"}
  *Sex, n (%)*                                                                           
  Men                           35 (67.3)                  32 (62.7)                     0.7[†](#tblfn2){ref-type="table-fn"}
  Women                         17 (32.6)                  19 (37.2)                     0.7[†](#tblfn2){ref-type="table-fn"}
  Mean (SD) stone size, mm      5.4 (1.5)                  5.6 (1.2)                     0.4[⁎](#tblfn1){ref-type="table-fn"}
  Stone side: right/left, *n*   32/20                      28/23                         0.6[†](#tblfn2){ref-type="table-fn"}

*t*-Test.

Chi-squared test.

###### 

Study outcomes.

  Outcome                                            Group A (silodosin 8 mg)   Group B (tamsulosin 0.4 mg)   *P*
  -------------------------------------------------- -------------------------- ----------------------------- ------------------------------------------
  Stone clearance rate (primary endpoint), *n* (%)   43 (83)                    29 (57)                       0.007[†](#tblfn4){ref-type="table-fn"}
  *Mean (SD)*                                                                                                 
  Stone expulsion time (secondary endpoint), days    13.3 (4.1)                 16.7 (5.2)                    \<0.001[⁎](#tblfn3){ref-type="table-fn"}
  Visual analogue scale score                        2.2 (0.7)                  2.4 (0.4)                     0.07[⁎](#tblfn3){ref-type="table-fn"}
  Pain episodes, *n*                                 1.3 (0.4)                  1.4 (0.3)                     0.15[⁎](#tblfn3){ref-type="table-fn"}
  Analgesic use: diclofenac sodium, mg               239 (12.2)                 243 (11.9)                    0.09[⁎](#tblfn3){ref-type="table-fn"}

*t*-Test.

Chi-squared test.
